ANI Pharmaceuticals Inc

ANIP

73.940USD

-0.200-0.27%

Market hours （ET）Quotes delayed by 15 min

ANI Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

8 / 157

Overall Ranking

46 / 4542

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive

ANI Pharmaceuticals Inc Highlights

StrengthsRisks

ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company engaged in developing, manufacturing, and commercializing therapeutics. Its Rare Disease and Brands segment consists of two reporting units. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel, ILUVIEN and YUTIQ. In addition, the Brands reporting unit includes a portfolio of over 16 brand products that are principally sold in genericized markets. Its Generics and Other segment consist of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 81.46% year-on-year.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 883.37M.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD .

Fairly Valued

The company’s latest PE is 20.80, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 21.97M shares, increasing 0.07% quarter-over-quarter.

Held by HOTCHKIS & WILEY

Star Investor HOTCHKIS & WILEY holds 74.78K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 1.66.

Analyst Rating

Based on 8 analysts

Buy

Current Rating

110.000

Target Price

+48.37%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of ANI Pharmaceuticals Inc is 8.60, ranking 40 out of 157 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 247.06M, representing a year-over-year increase of 29.64%, while its net profit experienced a year-over-year increase of 337.66%.

Score

Industry at a Glance

Previous score

8.60

Change

0



Financials

7.24

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

8.37

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

9.81

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.58

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of ANI Pharmaceuticals Inc is 8.52, ranking 15 out of 157 in the Pharmaceuticals industry. Its current P/E ratio is 20.80, which is 467.59% below the recent high of 118.04 and 794.69% above the recent low of -144.47.

Score

Industry at a Glance

Previous score

8.52

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 8/157

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of ANI Pharmaceuticals Inc is 8.50, ranking 28 out of 157 in the Pharmaceuticals industry. The average price target is 107.50, with a high of 121.00 and a low of 90.00.

Score

Industry at a Glance

Previous score

8.50

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of ANI Pharmaceuticals Inc is 7.03, ranking 46 out of 157 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 77.14 and the support level at 69.32, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.32

Change

-0.29

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of ANI Pharmaceuticals Inc is 10.00, ranking 1 out of 157 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 100.49%, representing a quarter-over-quarter decrease of 2.69%. The largest institutional shareholder is The Vanguard, holding a total of 1.30M shares, representing 5.81% of shares outstanding, with 6.68% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

2.34M

-1.24%

The Vanguard Group, Inc.

Star Investors

1.27M

+0.01%

Meridian Venture Partners

1.01M

-12.88%

State Street Investment Management (US)

711.71K

-0.62%

Esjay L.L.C,

632.62K

-24.02%

Global Alpha Capital Management Ltd.

630.59K

-26.85%

Dimensional Fund Advisors, L.P.

505.43K

-8.75%

Soleus Capital Management, L.P.

340.24K

+570.52%

Tang Capital Management, LLC

317.50K

--



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of ANI Pharmaceuticals Inc is 6.97, ranking 45 out of 157 in the Pharmaceuticals industry. The company's beta value is 0.46. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. ANI Pharmaceuticals Inc’s latest ESG disclosure leads the Pharmaceuticals industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.

ANI Pharmaceuticals Inc

ANIP

8.23 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

United Therapeutics Corp

UTHR

8.81 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Innoviva Inc

INVA

8.56 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Mckesson Corp

MCK

8.40 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Catalyst Pharmaceuticals Inc

CPRX

8.37 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Jazz Pharmaceuticals PLC

JAZZ

8.35 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment